Novo Nordisk AS ADR | - | 14.76% | - | - | 5,656 |
LLY | 14.01% | 771.75 | -3.45% | 536 | |
Innovent Biologics Inc | - | 7.62% | - | - | 23,000 |
Hims & Hers Health Inc Ordinary Shares - Class A | - | 6.48% | - | - | 3,519 |
4519 | 5.24% | 6,800.0 | -0.72% | 3,100 | |
TEVA | 4.96% | 16.04 | -2.31% | 8,694 | |
WST | 4.63% | 221.05 | -1.53% | 640 | |
AstraZeneca PLC ADR | - | 4.53% | - | - | 1,874 |
ROG | 4.51% | 255.40 | +0.16% | 418 | |
PFE | 4.47% | 24.61 | -2.92% | 5,592 |
Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF is an exchange traded fund launched and managed by Amplify Investments LLC. The fund is co-managed by Penserra Capital Management LLC. It invests in public equity markets of global region. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences, pharmaceuticals, GLP-1 agonist drugs, drug manufacturers and enablers engaged in outsourced development and manufacturing of GLP-1 agonist drugs sectors. It invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the VettaFi Weight Loss Drug & Treatment Index, by using full replication technique. Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF was formed on May 21, 2024 and is domiciled in the United States.